GE HealthCare Technologies Inc. - Common Stock (GEHC)
81.96
+1.74 (2.17%)
NASDAQ · Last Trade: Dec 3rd, 11:31 AM EST
Detailed Quote
Previous Close
80.22
Open
80.21
Bid
81.91
Ask
81.98
Day's Range
80.10 - 82.43
52 Week Range
57.65 - 94.80
Volume
1,213,477
Market Cap
37.21B
PE Ratio (TTM)
16.93
EPS (TTM)
4.8
Dividend & Yield
0.1400 (0.17%)
1 Month Average Volume
4,163,012
Chart
About GE HealthCare Technologies Inc. - Common Stock (GEHC)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions. The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment. Read More
University of Rochester Medical Center (URMC) and GE HealthCare (Nasdaq: GEHC) announce a Care Alliance to build advanced capabilities across URMC’s footprint in upstate New York, including a center of excellence in its Imaging Sciences department, the addition of diagnostic tracer production for molecular imaging applications, and the standardization of patient monitoring across the entire UR Medicine health system.
At the Radiological Society of North America (RSNA) 2025 Annual Meeting, GE HealthCare (Nasdaq: GEHC) is showcasing several innovations brought to life through an expanded collaboration with NVIDIA. This collaboration underscores GE HealthCare’s ongoing commitment to integrating advanced technologies that aim to transform healthcare delivery and improve patient care. The company is leveraging NVIDIA’s offerings and expertise in areas of physical AI, high performance computing, and simulation, which has the potential to reduce manual tasks, increase patient comfort, and alleviate radiologist burnout through AI-powered assistance.
GE HealthCare (Nasdaq: GEHC) today unveiled the Allia™ Moveoi, an image guiding solution designed to enhance mobility and flexibility and redefine the way clinicians deliver care in the interventional suite. This new Allia platform features a slim, compact, cable-free C-arm, allowing full movement and patient access, while aiming to deliver outstanding image quality. To help care teams work with ease, Allia Moveo features a wide-bore C-arm designed to enable cone beam computed tomography (CBCT) that accommodates a diverse patient population, an ergonomic design and AI-powered tools intended to provide a seamless workflow, offering patients a smooth, more personalized procedure.
At this year’s Radiological Society of North America’s (RSNA) 2025 Annual Meeting, GE HealthCare (Nasdaq: GEHC) will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a century, GE HealthCare has stood at the intersection of medicine and technology—helping clinicians see more, understand more, and do more for their patients. What began with some of the world’s earliest technology innovations in medical imaging has evolved into a strong, global focus to advancing precision care.
GE HealthCare (Nasdaq: GEHC) today announced the 510(k) submissions to the U.S. Food and Drug Administration (FDA) seeking clearance for next-generation SIGNA™ MRI technology. Unveiled at the Radiological Society of North America’s 2025 Annual Meeting, these differentiated solutions are part of a wave of new GE HealthCare innovations aimed at tackling some of the most complex challenges in healthcare. Designed to enhance precision diagnosis for clinicians and help clinicians improve patient outcomes, the new technologies include GE HealthCare’s4 1.5T MRI system, both equipped with an AI-powered workflow platform designed for end-to-end exam efficiency.
GE HealthCare (Nasdaq: GEHC) announced today that it has received FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. Powered by deep learning, Pristina Recon DL sets a new standard in image definition and sharpness.
GE HealthCare (Nasdaq: GEHC) announced the introduction of Genesis™ Radiology Workspace, a next-generation solution designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision. At the center of this innovation is Genesis™ View, 510(k) pending2, a powerful new viewer designed to be a fast diagnostic, zero-footprint viewer – streamlining radiology workflows with the intent to enhance patient care while being fully accessible from any location.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the fourth quarter of 2025 payable on February 13, 2026, to all shareholders of record as of January 9, 2026.
Paris, France – November 24, 2025 – French medtech innovator AI-Stroke has successfully closed a substantial US$4.6 million seed funding round, a pivotal step in advancing its groundbreaking artificial intelligence technology aimed at transforming pre-computed tomography (CT) stroke triage. Announced on November 18, 2025, this significant investment underscores a growing confidence in AI-driven solutions to [...]
GE HealthCare today announced the submission of a 510(k) to the U.S. FDA seeking clearance for Photonova™ Spectra,i its new photon-counting computed tomography (PCCT) system with advanced AI algorithmsii – marking a major milestone in the company’s decades-long history of CT innovation. Built on GE HealthCare’s proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver remarkable spectral and spatial resolution for ultra-high-definition (UHD) imaging with wide coverage, seeking to enable fast acquisition speeds, precise visualization of anatomical structures and enhanced material separation.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
GE HealthCare (Nasdaq: GEHC) announced it has entered into an agreement to acquire Intelerad, a leading medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition demonstrates GE HealthCare’s continued commitment to cloud-enabled and AI-powered solutions across care settings and furthers the company’s aim to triple its offerings of cloud-enabled products by 2028.
In a pivotal shift for artificial intelligence in healthcare, researchers and developers are increasingly focusing on the reliability and diagnostic accuracy of AI methods for processing medical images, moving decisively beyond mere aesthetic quality. This re-prioritization underscores a maturing understanding of AI's critical role in clinical settings, where the stakes are inherently high, and trust [...]
GE HealthCare (Nasdaq: GEHC) today announced that Cardiovascular Associates of America (CVAUSA), the largest network of private cardiology groups in the U.S., plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography (PET) radiotracer Flyrcado™ (flurpiridaz F 18) injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging (MPI) in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.
Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized treatment. By intelligently integrating diverse data types—from medical imaging and genomic profiles to clinical notes and real-world patient data—these advanced AI systems offer a holistic and nuanced understanding of [...]
GE HealthCare’s third quarter saw revenue and adjusted profit come in slightly above Wall Street’s expectations, but the market reacted negatively, reflecting concerns about margin pressures. Management pointed to strong demand across imaging and pharmaceutical diagnostics as primary drivers, with robust orders growth and new enterprise deals contributing to a healthy backlog. However, increased tariffs and a product hold in Patient Care Solutions weighed on profitability. CEO Peter Arduini noted, “We delivered robust orders growth of 6% with growth across all segments,” while CFO Jay Saccaro highlighted that tariff impacts reduced adjusted EBIT margin by 180 basis points, partially offset by volume and pricing gains.
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
